Table 3.
CT presentations of immunocompromised and non-immunocompromised IPA patients
| IPA patients (n = 254) | Immunocompromised (n = 66) |
Non-immunocompromised (n = 188) | p value | |
|---|---|---|---|---|
| Angio-invasive signs | ||||
| cavity | 102 (40.2%) | 31 (47%) | 71 (37.8%) | 0.189 |
| air crescent sign | 29 (11.4%) | 9 (13.6%) | 20 (10.6%) | 0.510 |
| soft-tissue mass | 80 (31.5%) | 24 (36.4%) | 56 (29.8%) | 0.322 |
| wedge shaped consolidation | 25 (9.8%) | 11 (16.7%) | 14 (7.4%) | 0.031* |
| halo sign | 52 (20.5%) | 17 (25.8%) | 35 (18.6%) | 0.216 |
| Airway invasive signs | ||||
| centrilobular nodules | 95 (37.4%) | 25 (37.9%) | 70 (37.2%) | 0.926 |
| patches distributing along the airway | 157 (61.8%) | 30 (45.5%) | 127 (67.6%) | 0.001* |
| airway wall thickness | 90 (35.4%) | 11 (16.7%) | 79 (42.0%) | < 0.001* |
| tree in bud sign | 93 (36.6%) | 18 (27.3%) | 75 (39.9%) | 0.067 |
| pleural effusion | 70 (27.6%) | 17 (25.8%) | 53 (28.2%) | 0.703 |
| atelectasis | 15 (5.9%) | 3 (4.5%) | 12 (6.4%) | 0.586 |
EORTC/MSG European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group
note: * p<0.05